Perceptive Advisors
Latest statistics and disclosures from Perceptive Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CERE, FOLD, IOVA, ACLX, NUVL, and represent 27.01% of Perceptive Advisors's stock portfolio.
- Added to shares of these 10 stocks: IOVA (+$108M), FUSN (+$87M), VKTX (+$82M), MDGL (+$75M), NBIX (+$74M), ITCI (+$66M), APGE (+$58M), PCVX (+$58M), Cg Oncology (+$57M), PRAX (+$50M).
- Started 26 new stock positions in ENGN, SYRS, KURA, IBRX, LIVN, CNTA, PRCT, Arrivent Biopharma, PRAX, Kyverna Therapeutics.
- Reduced shares in these 10 stocks: LIANY (-$257M), XBI (-$176M), Cymabay Therapeutics (-$95M), Rayzebio (-$46M), ACLX (-$43M), ABBV (-$24M), ASND (-$17M), MIRM (-$16M), EYPT (-$16M), TNGX (-$11M).
- Sold out of its positions in ACAD, ASND, BCAB, Caremax, Cymabay Therapeutics, CYTK, KRON, LPTX, LIANY, MIRM. Ambrx Biopharma, OLMA, Rayzebio, RGNX, TNGX, TERN, TVTX.
- Perceptive Advisors was a net buyer of stock by $713M.
- Perceptive Advisors has $5.8B in assets under management (AUM), dropping by 29.19%.
- Central Index Key (CIK): 0001224962
Tip: Access up to 7 years of quarterly data
Positions held by Perceptive Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 108 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cerevel Therapeutics Hldng I (CERE) | 7.9 | $456M | 11M | 42.27 |
|
|
| Amicus Therapeutics (FOLD) | 5.7 | $331M | 28M | 11.78 |
|
|
| Iovance Biotherapeutics (IOVA) | 5.0 | $286M | +60% | 19M | 14.82 |
|
| Arcellx Common Stock (ACLX) | 4.8 | $274M | -13% | 3.9M | 69.55 |
|
| Nuvalent Inc-a (NUVL) | 3.6 | $209M | -4% | 2.8M | 75.09 |
|
| Apogee Therapeutics (APGE) | 3.1 | $179M | +47% | 2.7M | 66.45 |
|
| Inhibrx (INBX) | 2.6 | $149M | 4.3M | 34.96 |
|
|
| Fusion Pharmaceuticals (FUSN) | 2.5 | $146M | +148% | 6.8M | 21.32 |
|
| Rhythm Pharmaceuticals (RYTM) | 2.5 | $142M | +51% | 3.3M | 43.33 |
|
| Vaxcyte (PCVX) | 2.3 | $132M | +77% | 1.9M | 68.31 |
|
| Soleno Therapeutics (SLNO) | 2.3 | $132M | 3.1M | 42.80 |
|
|
| Medtronic SHS (MDT) | 2.2 | $125M | +46% | 1.4M | 87.15 |
|
| Madrigal Pharmaceuticals (MDGL) | 2.0 | $115M | +184% | 430k | 267.04 |
|
| Springworks Therapeutics (SWTX) | 1.9 | $111M | +15% | 2.3M | 49.22 |
|
| Neurocrine Biosciences (NBIX) | 1.9 | $111M | +197% | 804k | 137.92 |
|
| Immunovant (IMVT) | 1.7 | $99M | +31% | 3.1M | 32.31 |
|
| Spyre Therapeutics Com New (SYRE) | 1.7 | $97M | 2.6M | 37.93 |
|
|
| Biohaven (BHVN) | 1.6 | $94M | 1.7M | 54.69 |
|
|
| Solid Biosciences Com New (SLDB) | 1.6 | $92M | +97% | 6.9M | 13.32 |
|
| Astria Therapeutics (ATXS) | 1.6 | $91M | +61% | 6.5M | 14.07 |
|
| Axsome Therapeutics (AXSM) | 1.5 | $88M | +6% | 1.1M | 79.80 |
|
| Viking Therapeutics (VKTX) | 1.4 | $82M | NEW | 994k | 82.00 |
|
| Evolus (EOLS) | 1.4 | $81M | +45% | 5.8M | 14.00 |
|
| Lyra Therapeutics (LYRA) | 1.4 | $79M | 13M | 6.22 |
|
|
| Disc Medicine (IRON) | 1.3 | $77M | +21% | 1.2M | 62.26 |
|
| Cargo Therapeutics (CRGX) | 1.3 | $77M | 3.4M | 22.32 |
|
|
| Intra Cellular Therapies (ITCI) | 1.3 | $73M | +877% | 1.1M | 69.20 |
|
| Natera (NTRA) | 1.2 | $69M | -10% | 757k | 91.46 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.2 | $69M | +17% | 1.5M | 46.81 |
|
| Meiragtx Holdings (MGTX) | 1.2 | $69M | 11M | 6.07 |
|
|
| Sarepta Therapeutics (SRPT) | 1.2 | $68M | +16% | 526k | 129.46 |
|
| Miragen Therapeutics (VRDN) | 1.1 | $64M | +111% | 3.7M | 17.51 |
|
| Verona Pharma Sponsored Ads (VRNA) | 1.1 | $61M | -2% | 3.8M | 16.09 |
|
| Applied Therapeutics (APLT) | 1.0 | $58M | +85% | 8.5M | 6.80 |
|
| Cg Oncology | 1.0 | $57M | NEW | 1.3M | 43.90 |
|
| CryoLife (AORT) | 1.0 | $57M | +186% | 2.7M | 21.16 |
|
| Arvinas Ord (ARVN) | 0.9 | $51M | +249% | 1.2M | 41.28 |
|
| Celcuity (CELC) | 0.9 | $51M | +59% | 2.4M | 21.60 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.9 | $50M | NEW | 822k | 61.02 |
|
| Rocket Pharmaceuticals (RCKT) | 0.8 | $49M | +5% | 1.8M | 26.94 |
|
| Immatics SHS (IMTX) | 0.8 | $48M | +31% | 4.6M | 10.51 |
|
| Tarsus Pharmaceuticals (TARS) | 0.8 | $47M | 1.3M | 36.35 |
|
|
| Bridgebio Pharma (BBIO) | 0.8 | $44M | -19% | 1.4M | 30.92 |
|
| Adma Biologics (ADMA) | 0.7 | $43M | 6.4M | 6.60 |
|
|
| Edgewise Therapeutics (EWTX) | 0.7 | $42M | +317% | 2.3M | 18.24 |
|
| Verrica Pharmaceuticals (VRCA) | 0.7 | $42M | 7.1M | 5.92 |
|
|
| Intuitive Surgical Com New (ISRG) | 0.7 | $41M | +85% | 102k | 399.09 |
|
| Xenon Pharmaceuticals (XENE) | 0.7 | $38M | -18% | 892k | 43.05 |
|
| Nautilus Biotechnology (NAUT) | 0.6 | $37M | 13M | 2.94 |
|
|
| Akero Therapeutics (AKRO) | 0.6 | $35M | +43% | 1.4M | 25.26 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.6 | $35M | NEW | 3.1M | 11.30 |
|
| Landos Biopharma Com New (LABP) | 0.6 | $32M | 1.5M | 21.48 |
|
|
| Ocular Therapeutix (OCUL) | 0.5 | $30M | NEW | 3.3M | 9.10 |
|
| Treace Med Concepts (TMCI) | 0.5 | $30M | +84% | 2.3M | 13.05 |
|
| Cabaletta Bio (CABA) | 0.5 | $29M | -14% | 1.7M | 17.06 |
|
| Protagonist Therapeutics (PTGX) | 0.5 | $29M | +159% | 994k | 28.93 |
|
| Irhythm Technologies (IRTC) | 0.5 | $28M | NEW | 245k | 116.00 |
|
| Aldeyra Therapeutics (ALDX) | 0.5 | $28M | 8.6M | 3.27 |
|
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.5 | $28M | +136% | 4.3M | 6.38 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.4 | $22M | 3.0M | 7.15 |
|
|
| Pepgen (PEPG) | 0.4 | $21M | NEW | 1.4M | 14.70 |
|
| Revolution Medicines (RVMD) | 0.3 | $20M | -24% | 619k | 32.23 |
|
| Abbvie (ABBV) | 0.3 | $19M | -55% | 107k | 182.10 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.3 | $17M | +311% | 339k | 50.23 |
|
| Engene Holdings (ENGN) | 0.3 | $17M | NEW | 999k | 16.95 |
|
| Livanova SHS (LIVN) | 0.3 | $17M | NEW | 299k | 55.94 |
|
| Athira Pharma (ATHA) | 0.3 | $15M | 5.4M | 2.74 |
|
|
| Tactile Systems Technology, In (TCMD) | 0.3 | $15M | +27% | 903k | 16.25 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.2 | $13M | +4% | 2.5M | 5.27 |
|
| Axogen (AXGN) | 0.2 | $13M | +92% | 1.6M | 8.07 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $12M | -55% | 590k | 20.67 |
|
| Zymeworks Del (ZYME) | 0.2 | $11M | 1.1M | 10.52 |
|
|
| Rapt Therapeutics (RAPT) | 0.2 | $11M | -42% | 1.2M | 8.98 |
|
| Tyra Biosciences (TYRA) | 0.2 | $11M | +85% | 669k | 16.40 |
|
| Procept Biorobotics Corp (PRCT) | 0.2 | $10M | NEW | 211k | 49.42 |
|
| Morphic Hldg (MORF) | 0.2 | $10M | +405% | 288k | 35.20 |
|
| Silverback Therapeutics (SPRY) | 0.2 | $8.9M | NEW | 867k | 10.22 |
|
| Arcutis Biotherapeutics (ARQT) | 0.1 | $7.4M | NEW | 750k | 9.91 |
|
| Arrivent Biopharma | 0.1 | $7.4M | NEW | 415k | 17.86 |
|
| Precision Biosciences Com New | 0.1 | $6.5M | NEW | 481k | 13.56 |
|
| Cogent Biosciences (COGT) | 0.1 | $5.9M | -21% | 883k | 6.72 |
|
| Kalvista Pharmaceuticals (KALV) | 0.1 | $5.9M | NEW | 500k | 11.86 |
|
| Immunitybio (IBRX) | 0.1 | $5.7M | NEW | 1.1M | 5.37 |
|
| Amylyx Pharmaceuticals Call Option (AMLX) | 0.1 | $5.6M | +5% | 2.0M | 2.84 |
|
| Macrogenics (MGNX) | 0.1 | $5.6M | -38% | 378k | 14.72 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs | 0.1 | $5.2M | NEW | 500k | 10.40 |
|
| X4 Pharmaceuticals (XFOR) | 0.1 | $4.9M | 3.5M | 1.39 |
|
|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 0.1 | $4.7M | -97% | 50k | 94.89 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.1 | $4.2M | 82k | 50.90 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.1 | $4.1M | NEW | 175k | 23.65 |
|
| Absci Corp (ABSI) | 0.1 | $4.0M | NEW | 700k | 5.68 |
|
| Female Health (VERU) | 0.1 | $3.9M | 5.6M | 0.70 |
|
|
| Kyverna Therapeutics | 0.1 | $3.7M | NEW | 150k | 24.84 |
|
| Trinity Biotech Spons Adr New | 0.1 | $3.7M | NEW | 1.8M | 2.04 |
|
| Nanobiotix Sponsored Ads (NBTX) | 0.1 | $3.6M | 555k | 6.50 |
|
|
| Envveno Medical (NVNO) | 0.1 | $3.4M | 623k | 5.44 |
|
|
| Novavax Com New Put Option (NVAX) | 0.1 | $3.3M | -50% | 700k | 4.78 |
|
| Revance Therapeutics (RVNC) | 0.1 | $3.0M | NEW | 600k | 4.92 |
|
| Agios Pharmaceuticals Call Option (AGIO) | 0.1 | $2.9M | NEW | 100k | 29.24 |
|
| Forte Biosciences (FBRX) | 0.0 | $2.3M | 3.3M | 0.70 |
|
|
| Singular Genomics Systems In (OMIC) | 0.0 | $1.1M | 2.1M | 0.51 |
|
|
| Kura Oncology (KURA) | 0.0 | $1.0M | NEW | 48k | 21.33 |
|
| Vbi Vaccines Inc Cda Com New (VBIV) | 0.0 | $757k | -8% | 1.3M | 0.60 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.0 | $625k | NEW | 117k | 5.35 |
|
| Caremax Cl A New (CMAX) | 0.0 | $591k | NEW | 123k | 4.82 |
|
| Revolution Medicines *w Exp 12/17/202 (RVMDW) | 0.0 | $46k | 250k | 0.18 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $5.0k | 167k | 0.03 |
|
|
| Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $1.0k | 60k | 0.02 |
|
Past Filings by Perceptive Advisors
SEC 13F filings are viewable for Perceptive Advisors going back to 2010
- Perceptive Advisors 2024 Q1 filed May 15, 2024
- Perceptive Advisors 2023 Q4 restated filed Feb. 26, 2024
- Perceptive Advisors 2023 Q4 filed Feb. 14, 2024
- Perceptive Advisors 2023 Q3 filed Nov. 14, 2023
- Perceptive Advisors 2023 Q2 restated filed Aug. 24, 2023
- Perceptive Advisors 2023 Q2 filed Aug. 14, 2023
- Perceptive Advisors 2023 Q1 restated filed May 16, 2023
- Perceptive Advisors 2023 Q1 filed May 15, 2023
- Perceptive Advisors 2022 Q4 filed Feb. 14, 2023
- Perceptive Advisors 2022 Q3 filed Nov. 14, 2022
- Perceptive Advisors 2022 Q2 filed Aug. 15, 2022
- Perceptive Advisors 2022 Q1 filed May 16, 2022
- Perceptive Advisors 2021 Q4 amended filed May 4, 2022
- Perceptive Advisors 2021 Q4 restated filed April 13, 2022
- Perceptive Advisors 2021 Q4 filed Feb. 14, 2022
- Perceptive Advisors 2021 Q3 restated filed Dec. 3, 2021